Picture of HBM Holdings logo

2142 HBM Holdings Share Price

0.000.00%
hk flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapValue Trap

Momentum

Relative Strength (%)
1m-27.21%
3m-34.86%
6m-33.03%
1yr-54.3%
Volume Change (%)
10d/3m-34.13%
Price vs... (%)
52w High-54.07%
50d MA-24.63%
200d MA-28.61%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital16.16%
Return on Equity21.42%
Operating Margin29.67%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of HBM Holdings EPS forecast chart

Profile Summary

HBM Holdings Ltd is an investment holding company mainly engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. The Company’s products include batoclimab, mainly used for immune thrombocytopenia (ITP), graves’ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD); and tanfanercept, mainly used for dry eye disease (DED). In addition, the Company researches and develops immuno-oncology portfolio, including internally developed next-generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    December 31st, 2023
    Incorporated
    July 20th, 2016
    Public Since
    December 10th, 2020
    No. of Employees
    154
    Sector
    Pharmaceuticals
    Industry
    Healthcare
    Exchange
    hk flag iconStock Exchange of Hong Kong Limited
    Shares in Issue
    770,142,410

    2142 Share Price Performance

    Upcoming Events for 2142

    Hbm Holdings Ltd Annual Shareholders Meeting

    Half Year 2024 Hbm Holdings Ltd Earnings Release

    Similar to 2142

    Picture of 3D Medicines logo

    3D Medicines

    hk flag iconStock Exchange of Hong Kong Limited

    Picture of 3SBio logo

    3SBio

    hk flag iconStock Exchange of Hong Kong Limited

    Picture of AIM Vaccine Co logo

    AIM Vaccine Co

    hk flag iconStock Exchange of Hong Kong Limited

    Picture of Ascletis Pharma logo

    Ascletis Pharma

    hk flag iconStock Exchange of Hong Kong Limited

    Picture of Asymchem Laboratories Tianjin Co logo

    Asymchem Laboratories Tianjin Co

    hk flag iconStock Exchange of Hong Kong Limited

    FAQ